1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hearing Disorders - Pipeline Review, H1 2014

Hearing Disorders - Pipeline Review, H1 2014

  • June 2014
  • -
  • Global Markets Direct
  • -
  • 76 pages

Hearing Disorders - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Hearing Disorders - Pipeline Review, H1 2014’, provides an overview of the Hearing Disorders’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hearing Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hearing Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hearing Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hearing Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hearing Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hearing Disorders - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Hearing Disorders Overview 8
Therapeutics Development 9
Pipeline Products for Hearing Disorders - Overview 9
Pipeline Products for Hearing Disorders - Comparative Analysis 10
Hearing Disorders - Therapeutics under Development by Companies 11
Hearing Disorders - Therapeutics under Investigation by Universities/Institutes 13
Hearing Disorders - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Hearing Disorders - Products under Development by Companies 17
Hearing Disorders - Products under Investigation by Universities/Institutes 18
Hearing Disorders - Companies Involved in Therapeutics Development 19
Adherex Technologies Inc. 19
Quark Pharmaceuticals, Inc. 20
Novartis AG 21
Living Cell Technologies Limited 22
Fate Therapeutics, Inc. 23
Sound Pharmaceuticals, Inc. 24
Pharmicell Co., Ltd. 25
Otologic Pharmaceutics, Inc. 26
UniQure NV 27
AudioCure Pharma GmbH 28
Hearing Disorders - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
sodium thiosulfate - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
SPI-1005 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ebselen - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
CGF-166 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
AUT-00063 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
siRNA for CNS Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
AMT-090 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
SPI-5557 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
NTCELL - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Hearing Restoration Program - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Small Molecules for Hearing Loss - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
(acetylcysteine + disufenton sodium) - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Neuroprotectin D1 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
AC-002 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Cellgram for Severe Hard of Hearing - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Drugs to Inhibit Rho Kinase for Hearing Loss - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Hearing Disorders - Recent Pipeline Updates 59
Hearing Disorders - Dormant Projects 65
Hearing Disorders - Product Development Milestones 66
Featured News and Press Releases 66
Jun 02, 2014: Adherex Announces Results From Two Sodium Thiosulfate Phase 3 Studies Presented at the 50th American Society of Clinical Oncology Meeting 66
Apr 22, 2014: Adherex Announces Two Sodium Thiosulfate Presentations for Prevention of Ototoxicity in Children at ASCO Meeting 68
Nov 05, 2013: Sound Pharmaceuticals successfully completes its first Phase 2 clinical trial with SPI-1005 involving iPod or noise induced hearing loss 69
Jan 04, 2012: Research Publication Shows AM-111's Otoprotective Effect In Cochlear Ischemia 70
Oct 07, 2011: Adherex Reports Meeting With FDA'S Pediatric Subcommittee Of Oncologic Drugs Advisory Committee On Development Of Sodium Thiosulfate Injection 70
Mar 04, 2011: Auris Medical's AM-111 Protects Against Hearing Loss From Cochlear Implant Electrode Insertion Trauma 71
Jan 17, 2011: Auris Medical Starts Enrolment In Second Cohort Of Phase IIb Study With AM-111 72
Jun 28, 2010: Fate Therapeutics Receives Red Herring's North America 100 Award For Advancing Stem Cell Technology And New Medicines 72
Feb 04, 2010: Fate Therapeutics Receives Allowance Of First U.S. Patent For Induced Pluripotent Stem Cell Technology 73
Dec 01, 2009: Fate Therapeutics' IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables

Number of Products under Development for Hearing Disorders, H1 2014 9
Number of Products under Development for Hearing Disorders - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Hearing Disorders - Pipeline by Adherex Technologies Inc., H1 2014 19
Hearing Disorders - Pipeline by Quark Pharmaceuticals, Inc., H1 2014 20
Hearing Disorders - Pipeline by Novartis AG, H1 2014 21
Hearing Disorders - Pipeline by Living Cell Technologies Limited, H1 2014 22
Hearing Disorders - Pipeline by Fate Therapeutics, Inc., H1 2014 23
Hearing Disorders - Pipeline by Sound Pharmaceuticals, Inc., H1 2014 24
Hearing Disorders - Pipeline by Pharmicell Co., Ltd., H1 2014 25
Hearing Disorders - Pipeline by Otologic Pharmaceutics, Inc., H1 2014 26
Hearing Disorders - Pipeline by UniQure NV, H1 2014 27
Hearing Disorders - Pipeline by AudioCure Pharma GmbH, H1 2014 28
Assessment by Monotherapy Products, H1 2014 29
Assessment by Combination Products, H1 2014 30
Number of Products by Stage and Target, H1 2014 33
Number of Products by Stage and Mechanism of Action, H1 2014 36
Number of Products by Stage and Route of Administration, H1 2014 38
Number of Products by Stage and Molecule Type, H1 2014 40
Hearing Disorders Therapeutics - Recent Pipeline Updates, H1 2014 59
Hearing Disorders - Dormant Projects, H1 2014 65

List of Figures

Number of Products under Development for Hearing Disorders, H1 2014 9
Number of Products under Development for Hearing Disorders - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 29
Number of Products by Top 10 Target, H1 2014 31
Number of Products by Stage and Top 10 Target, H1 2014 32
Number of Products by Top 10 Mechanism of Action, H1 2014 34
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 35
Number of Products by Top 10 Route of Administration, H1 2014 37
Number of Products by Stage and Top 10 Route of Administration, H1 2014 38
Number of Products by Top 10 Molecule Type, H1 2014 39
Number of Products by Stage and Top 10 Molecule Type, H1 2014 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.